S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NASDAQ:AGTC

Applied Genetic Technologies Stock Forecast, Price & News

$3.23
-0.19 (-5.56 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.21
$3.48
50-Day Range
$3.18
$4.05
52-Week Range
$3.12
$9.67
Volume656,795 shs
Average Volume1.73 million shs
Market Capitalization$138.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.16
30 days | 90 days | 365 days | Advanced Chart
Receive AGTC News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.


Applied Genetic Technologies logo

About Applied Genetic Technologies

Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

745th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

112th out of 193 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions

Is Applied Genetic Technologies a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Applied Genetic Technologies stock.
View analyst ratings for Applied Genetic Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than Applied Genetic Technologies?

Wall Street analysts have given Applied Genetic Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Applied Genetic Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Applied Genetic Technologies' next earnings date?

Applied Genetic Technologies is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Applied Genetic Technologies
.

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) posted its quarterly earnings results on Wednesday, September, 22nd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.12. During the same quarter in the prior year, the firm posted ($0.56) earnings per share.
View Applied Genetic Technologies' earnings history
.

How has Applied Genetic Technologies' stock been impacted by COVID-19 (Coronavirus)?

Applied Genetic Technologies' stock was trading at $3.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AGTC stock has decreased by 15.9% and is now trading at $3.23.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AGTC?

7 brokerages have issued 1-year target prices for Applied Genetic Technologies' shares. Their forecasts range from $11.00 to $35.00. On average, they anticipate Applied Genetic Technologies' share price to reach $19.00 in the next year. This suggests a possible upside of 488.2% from the stock's current price.
View analysts' price targets for Applied Genetic Technologies
or view top-rated stocks among Wall Street analysts.

Who are Applied Genetic Technologies' key executives?

Applied Genetic Technologies' management team includes the following people:
  • Susan B. Washer, President, Chief Executive Officer & Director
  • Nnenna Ihekoromadu, VP-Clinical Research & Medical Affairs
  • Matthew Feinsod, Executive VP-Global Strategy & Development
  • Karen M. Carroll, Vice President-Clinical Development Operations
  • Janet C. Rae, Senior Vice President-Global Regulatory & Quality

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Who are Applied Genetic Technologies' major shareholders?

Applied Genetic Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Millennium Management LLC (4.10%), Vanguard Group Inc. (4.06%), BlackRock Inc. (2.42%), Dimensional Fund Advisors LP (1.55%), Geode Capital Management LLC (1.08%) and Morgan Stanley (0.53%).
View institutional ownership trends for Applied Genetic Technologies
.

Which institutional investors are selling Applied Genetic Technologies stock?

AGTC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Renaissance Technologies LLC, Northern Trust Corp, Wells Fargo & Company MN, Geode Capital Management LLC, Vanguard Group Inc., and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Applied Genetic Technologies
or view top insider-selling stocks.

Which institutional investors are buying Applied Genetic Technologies stock?

AGTC stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ergoteles LLC, GSA Capital Partners LLP, Morgan Stanley, Morgan Stanley, Knoll Capital Management LLC, Bridgeway Capital Management LLC, and Tibra Equities Europe Ltd.
View insider buying and selling activity for Applied Genetic Technologies
or or view top insider-buying stocks.

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $3.23.

How much money does Applied Genetic Technologies make?

Applied Genetic Technologies has a market capitalization of $138.10 million and generates $2.45 million in revenue each year. The biotechnology company earns $-45,890,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How many employees does Applied Genetic Technologies have?

Applied Genetic Technologies employs 83 workers across the globe.

What is Applied Genetic Technologies' official website?

The official website for Applied Genetic Technologies is www.agtc.com.

Where are Applied Genetic Technologies' headquarters?

Applied Genetic Technologies is headquartered at 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at (386) 462-2204 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.